MicuRx Pharmaceuticals was elected one of the top ten innovative drug companies in China in 2021

Recently, with its innovation achievements in the field of anti infection, MicuRx Pharmaceuticals was awarded the “Top 10 New Drug Innovation Companies of the Year” in the “2021 Drug Innovation Award Annual Selection”.

The “Annual Selection of Drug Innovation Award” is sponsored by the Securities Times. As the mainstream media of the securities market, the Securities Times has long been concerned about and committed to promoting the development of the pharmaceutical industry. Through the selection of China’s excellent drug innovation projects, excellent enterprises and outstanding figures, China’s innovative drug enterprises and innovative varieties are promoted at home and abroad to promote the improvement of China’s drug innovation ability.

Since the establishment of MicuRx Pharmaceuticals in 2007, it has adhered to the principle of “Better therapy through superior medicine”, and brought products that can better meet clinical needs with rich experience in the research and development of anti infective drugs.

In 2021, the MicuRx’s blockbuster antimicrobial infection drug, contezolid, was successfully marketed in China and included in the medical insurance in 2022. In May this year, the global phase III clinical trial of MRX-4 for injection and contezolid tablets for sequential treatment of diabetes foot infection started the first patient administration, achieving the momentum of expansion.

With the recognition of the highly anticipated industry, MicuRx Pharmaceuticals will continue to develop more R&D pipelines and promote the innovation of the global anti infection pattern. Undertake the responsibility of China’s innovative pharmaceutical enterprises and inject new hope into the human anti infection war.